MSB 7.69% $1.19 mesoblast limited

Ann: Mesoblast Update on COVID-19 ARDS Trial, page-423

  1. 10,751 Posts.
    lightbulb Created with Sketch. 549
    That is halting. They are not enrolling any more patients to get up to their 300 patients. They are stopping at their current enrolment but are completing the trial with the 223 that they already have which will provide them with more data and enable them to analyse their data on their secondary endpoints.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.